64 results about "Adriamycinol" patented technology

The invention discloses a single cell activity evaluation method based on cell nucleus geometric parameters and a Bayesian framework, which comprises the following steps: establishing a HeLa cell activity gradient model through adriamycin induction, carrying out cell nucleus segmentation by adopting Cell pose 3.0 and extracting 26 geometric features, screening a high-confidence sample in combination with a Bayesian deep learning framework, and evaluating the activity of a single cell according to the high-confidence sample. And constructing a multi-modal feature fusion model to integrate geometric features and deep semantic features, and finally realizing unmarked and high-precision single cell activity evaluation. The method overcomes the limitation that a traditional technology depends on biochemical markers, has the advantages of being easy and convenient to operate, high in flux and high in interpretability, and provides an innovative technical means for tumor liquid biopsy and precise medical treatment.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention relates to the technical field of liposome preparation, and particularly discloses a nano liposome and a preparation method thereof.The method comprises the steps that distearoyl phosphatidyl ethanolamine, cholesterol, hydroxyl-terminated polyethylene glycol and mPEG-Hyd-PEG-SH are dissolved in a mixed solvent, and a lipid film is formed through rotary evaporation; hydrating with a PBS (Phosphate Buffer Solution) containing ammonium sulfate, and carrying out ultrasonic treatment to obtain primary emulsion; a doxorubicin solution is added for incubation, and drug loading is completed; the CD44 antibody and the drug-loaded liposome are coupled in a catalytic system, and are homogenized by a spiral microreactor. The problems of high immunogenicity, insufficient targeting, non-uniform particle size, uncontrollable drug release and complex preparation process of the existing PEG nano-liposome are solved, and the PEG nano-liposome has the advantages of low immunogenicity, high targeting, uniform and stable particle size, drug response release and easiness in large-scale production.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The method comprises the following steps: taking red ginseng, radix ophiopogonis and schisandra chinensis, carrying out water extraction and freeze drying to obtain freeze-dried powder, taking the freeze-dried powder, adding distilled water to dissolve the freeze-dried powder, adding the dissolved freeze-dried powder to a macroporous adsorption resin column, carrying out gradient elution with water, a 20% ethanol aqueous solution, a 50% ethanol aqueous solution and a 75% ethanol aqueous solution in sequence, and carrying out vacuum concentration to obtain the effective part of the pulse-activating decoction. From the beginning of sample loading, collecting every 300mL of effluent as a fraction, and collecting the fractions Fr1-Fr16; the chromatographic characteristics are analyzed, fractions with the same chromatographic characteristics are combined, the fractions Fr15-Fr16 are combined into a component yf-10, and the component yf-10 is the effective part of the pulse-activating decoction. According to the effective part disclosed by the invention, toxic parts are removed, so that H9c2 cell injury caused by adriamycin can be protected in a more effective, more stable and lower-toxicity manner, and the application of the component yf-10 in preparation of medicines for treating myocardial cell injury is prompted.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.

The invention discloses a method for producing high-purity doxorubicin through fermentation of streptomyces peucedanum var. Peucedanum X121-56-2 and in-situ extraction of LX-20 resin, which comprises the following steps: preparing a high-density seed solution through a specific seed culture medium and a culture process, and then inoculating the high-density seed solution into a fermentation culture medium containing a composite carbon and nitrogen source and LX-20 macroporous adsorption resin; and fermenting under the conditions of controlled temperature, pH, ventilation and dissolved oxygen. In the fermentation process, adriamycin is adsorbed by LX-20 resin in situ, the yield is effectively increased, and the extraction process is simplified. The specific strain is combined with the LX-20 resin technology for the first time, the adriamycin yield can reach 530 mg / L at the maximum under the 15L tank scale, the purity of a crude product directly extracted from the resin can reach 58%, and the method has the outstanding advantages of being high in yield and purity, low in cost, easy to amplify and the like.

The application discloses application of falcarinol-7-methyl ether and derivatives thereof in preparation of medicines and functional foods for delaying aging or immune regulation. In the application, the falcarinol-7-methyl ether and derivatives thereof are derived from falcarinol-7-methyl ether, and can effectively delay replicative senescence of mesenchymal stem cells, inhibit expression of aging-related markers of mouse liver and lung induced by adriamycin, improve grip strength of the mouse, enhance muscle function, and promote proliferation of T cells separated from human peripheral blood mononuclear cells, and have an immune regulation effect. Therefore, the falcarinol-7-methyl ether and derivatives thereof have good effects of improving telomerase activity, anti-aging and immune regulation, and can be developed into anti-aging or immune regulation products.

The application discloses a kind of degradable organic-inorganic hybrid nanoparticles based on calcium carbonate and preparation method thereof, the preparation method of the application uses calcium carbonate and amphiphilic block copolymer as raw material, uses amphiphilic block copolymer as organic matrix, and uses calcium carbonate aqueous solution as inorganic matrix, water-soluble drug doxorubicin hydrochloride (DOX·HCl) is wrapped in nanoparticle, and a kind of calcium carbonate-based hybrid nanoparticle is prepared using stirring mixing technology.The nanoparticle prepared by the application has moderate particle size, uniform particle size distribution, good biocompatibility and biodegradability, and is expected to become a novel drug delivery carrier.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of an anti-breast cancer medicine, and relates to the technical field of biological medicine and traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 60 parts of radix acanthopanacis semticosi, 30 to 60 parts of fructus ligustri lucidi, 30 to 60 parts of rhizoma bolbostemmae, 30 to 60 parts of caulis spatholobi, 30 to 60 parts of resina liquidamberis, 30 to 60 parts of tabasheer, 30 to 60 parts of gynura procumbens, 30 to 60 parts of aspongopus, 30 to 60 parts of pecteilis sumadai, 30 to 60 parts of thlaspi arvense, 30 to 60 parts of herba dendrobii and 10 to 30 parts of fructus ziziphi jujubae. The traditional Chinese medicine composition has the effects of strengthening the body resistance to eliminate pathogenic factors, detoxifying, removing stasis, activating blood, reducing phlegm, tonifying qi and nourishing yin. On the in-vitro level, the traditional Chinese medicine composition can remarkably inhibit proliferation, migration and invasion of BT549 and 4T1 cells at different concentrations. On the in-vivo level, the traditional Chinese medicine composition can significantly inhibit the growth speed, volume and quality of tumors, and shows an excellent tumor inhibition effect. And the anti-tumor effect of the compound can be improved after the compound is combined with adriamycin. The traditional Chinese medicine composition is expected to be further popularized and applied as an anti-breast cancer medicine.

The application belongs to the technical field of hydrogel, and particularly relates to a pH-sensitive composite hydrogel based on oxidized bacterial cellulose / cationic guar gum and a preparation method and application thereof. The application takes cationic guar gum (CGG) and oxidized bacterial cellulose (OBC) as gel wall materials, and takes adriamycin (DOX) as a loaded drug, and a CGG-OBC-DOX hydrogel is prepared through chemical cross-linking. Experimental results show that the obtained pH-sensitive hydrogel has the texture characteristics of traditional hydrogel, the internal cross-linking is strong, the structure is compact, the drug release amount at a low pH value is obviously higher than the release rate at a high pH value, the pH sensitivity and the slow release characteristics are good, the pH-sensitive hydrogel can be used for preparing an intelligent drug release system, and the hydrogel preparation does not need to add a chemical cross-linking agent, the process is simple, safe and non-toxic.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention relates to a cathepsin B sensitive fatty acid-adriamycin prodrug as well as albumin nanoparticles, a preparation method and application thereof, and belongs to the technical field of medicines. The cathepsin B sensitive fatty acid-adriamycin prodrug is a prodrug as shown in a formula (I), a geometric isomer thereof, and pharmaceutically acceptable salts, hydrates and solvates thereof, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by entrapping the cathepsin B sensitive fatty acid-adriamycin prodrug by using human / bovine serum albumin as a carrier. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug adriamycin after being taken by tumor cells and hydrolyzed by cathepsin B; therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.

The invention provides a biological membrane fusion nano-micelle, a drug-loaded biological membrane fusion nano-micelle as well as a preparation method and application thereof, and belongs to the technical field of medicines. The biological membrane fusion nano-micelle comprises an elastin-like polypeptide nano-micelle, a cancer cell membrane coating the surface of the elastin-like polypeptide nano-micelle, L-arginine located between the elastin-like polypeptide nano-micelle and the cancer cell membrane, and a fat-soluble photosensitizer located between phospholipid bilayers of the cancer cell membrane. The biological membrane fusion nano-micelle can bypass a traditional endocytosis way, and the treatment effect can be improved; the hydrophilic and hydrophobic structure of the elastin-like polypeptide nano-micelle is utilized to facilitate encapsulation of fat-soluble chemotherapeutic drugs (such as rapamycin or adriamycin), and a fat-soluble photosensitizer (such as a photosensitizer IR780 or a photosensitizer ICG) can be embedded into a phospholipid bilayer of a cancer cell membrane by utilizing the hydrophobic effect of the elastin-like polypeptide nano-micelle. Cancer synergistic chemotherapy, photodynamic therapy and gas therapy can be realized.

The invention discloses an effective part of a pulse-activating decoction as well as an extraction and purification method and application thereof, and the extraction and purification method comprises the following steps: taking red ginseng, radix ophiopogonis and schisandra chinensis as raw materials, adding water for extraction, and freeze-drying to obtain freeze-dried powder; dissolving the freeze-dried powder with distilled water, loading the dissolved powder on a macroporous adsorption resin column, carrying out gradient elution with water and a 20% ethanol aqueous solution in sequence, and separating fractions Fr1-Fr8; the chromatographic characteristics of each fraction are analyzed by using a C18 chromatographic column through a liquid chromatograph, the fractions with the same chromatographic characteristics are combined, the fractions Fr1-Fr4 are combined into a component yf-1, the fraction Fr5 is combined into a component yf-2, and the component yf-2 is the effective part of the pulse-activating decoction. According to the effective part disclosed by the invention, toxic parts are removed, so that H9c2 cell injury caused by adriamycin can be more effectively and stably protected with lower toxicity, and the application of the component yf-2 in preparation of medicines for treating myocardial cell injury is prompted.

The invention discloses application of rehmannia D in preparation of a product for preventing and / or treating myocardial injury, and belongs to the technical field of medicines. The myocardial injury comprises myocardial injury induced by doxorubicin (DOX), and experiments prove that the rehmannia D can obviously improve the heart function decline caused by the DOX; the myocardial cell atrophy induced by DOX can be obviously inhibited; the level of myocardial tissue fibrosis induced by DOX can be obviously inhibited; the DOX-induced myocardial tissue oxidative stress level can be obviously inhibited; in addition, DOX-induced myocardial tissue DNA damage (gamma-H2AX is taken as a marker) can be obviously inhibited. The invention proves that the rehmannia glycoside D can be used as a novel treatment means to be applied to treatment of adriamycin-induced myocardial injury, and the risk of treatment interruption or heart failure due to cardiotoxicity caused by chemotherapy of a patient can be possibly reduced, so that the disease burden of the patient and the pressure of a medical system are relieved.

The invention discloses a construction method and application of an adriamycin-induced zebrafish osteoporosis-like model, and the construction method comprises the following steps: by utilizing the characteristics of transparency and rapid bone development of zebrafish embryos and juvenile fishes, selecting the zebrafish embryos of 2dpf, and culturing the zebrafish embryos to 6dpf in an adriamycin aqueous solution of 20 mu m, so as to obtain the adriamycin-induced zebrafish osteoporosis-like model. Therefore, the visual zebrafish osteoporosis-like model is efficiently constructed, juvenile fish bodies are transparent, imaging is visual, bone development changes can be observed in vivo in real time, and visual evaluation of bone development injuries is achieved. The built zebrafish osteoporosis-like model clearly shows the systematic inhibition effect of chemotherapy drugs on bone formation and mineralization, has the advantages of being short in building period, easy and convenient to operate, high in repeatability and sensitive to drug reaction, can be used for rapid dose screening and intervention experiments, and has good application prospects. The method has great application potential in research of pathogenesis of CIOP, screening of anti-osteoporosis drugs and evaluation of curative effect of the anti-osteoporosis drugs.

The invention belongs to the technical field of biological medicine, and discloses a construction method and application of a podocyte specific S1PR1 gene knockout mouse model. A podocyte specific S1PR1 knockout mouse is constructed through a Cre-LoxP system, and then an FSGS model is constructed through doxorubicin injection. And verifying the model by using urine detection, serum detection, histopathology detection and molecular mechanism detection. Research finds that S1PR1 expression decline causes POLR2A splicing abnormity and expression decline through down-regulation of Xab2, and podocyte senescence and FSGS progress are induced. According to the invention, a related model is constructed for the first time, the regulation effect of the S1PR1-Xab2-POLR2A pathway in podocyte senescence is disclosed, a reliable tool is provided for researching FSGS pathogenesis, the potential of S1PR1 as a therapeutic target is determined, and the S1PR1 can be used for screening drugs for treating FSGS and has important clinical transformation value.

The invention discloses a preparation method and application of a folic acid targeted multi-drug synergistic nano polymer prodrug, and belongs to the technical field of nano biomedical materials. The preparation method comprises the following steps: on the basis of a click reaction, crosslinking polyfunctional 2-methylglycerol tripropiolate with adriamycin and resveratrol to prepare a nano polymer prodrug BDR with an acid response characteristic; a folic acid targeting molecule FA-PEG-NH2 is efficiently grafted by utilizing a click reaction, so that the active targeting nano polymer prodrug BDRP with high selectivity and multi-drug synergism is prepared. Experiments find that pH-sensitive chemical bonds with tumor microenvironment dual stimulation response are introduced into poly-prodrugs, intelligent controlled release of chemotherapeutic drugs at tumor parts can be achieved, and the bioavailability is improved; fA-PEG-NH2 is further modified, so that the active targeting efficiency is improved, the poly-prodrug has better specificity, selectivity and biological safety on tumor cells, and the treatment effect on cervical cancer can be improved.

The invention relates to the technical field of biological medicines, and particularly discloses application of a short peptide MPM in preparation of a reagent or a medicine for treating liver injury and heart injury. The amino acid sequence of the short peptide MPM is shown as any one of SEQ ID NO: 1 to SEQ ID NO: 3. The oligopeptide MPM and the reagent for promoting the content of the oligopeptide MPM can be used for treating liver injury and heart injury, and particularly can be used for treating acetaminophen-induced liver injury and adriamycin-induced heart injury.

The invention belongs to the technical field of medicines, discloses a compound in radix salviae miltiorrhizae and application of the compound in preparation of a medicine for treating heart failure, and particularly relates to application of a compound DS-31 with a novel structure in radix salviae miltiorrhizae or pharmaceutically acceptable salt, ester or solvate of the compound DS-31 in preparation of a medicine for preventing and / or treating heart failure diseases. Pharmacological tests prove that DS-31 has a protective effect on myocardial cell injury caused by adriamycin; in addition, the compound has an obvious protection effect on adriamycin-induced heart failure mice, myocarditis and fibrosis are relieved, abnormal heart reconstitution and dysfunction are reversed, the action mechanism is related to recovery of myocardial cell mitochondrial energy supply, and the compound has the potential of being developed into anti-heart failure drugs.

The invention discloses an application of a targeted ATAD3A phosphorylated polypeptide combined with adriamycin in preparation of a lung cancer treatment medicine. The targeted ATAD3A phosphorylated polypeptide is composed of a functional peptide with an amino acid sequence as shown in SEQ ID No.1 and a cell-penetrating peptide connected with the N end of the functional peptide. The research finds that in an A549 lung cancer cell line treated by adriamycin, the phosphorylation level of ATAD3A is obviously increased, and the ATAD3A is possibly closely related to tumor drug resistance. The TAT-polypeptide targeted to ATAD3A phosphorylation is designed to be combined with adriamycin for treatment, so that the sensitivity of lung cancer cells to adriamycin can be remarkably promoted, tumor growth is inhibited, and a good tumor treatment effect is achieved. Therefore, the invention provides a novel lung cancer combined treatment method which can effectively control the growth of the lung cancer.

The present application relates to the technical field of high polymer material, and particularly relates to a kind of mesoporous polymer microspheres and its preparation method and application, the present application is prepared by method in the case where not using surfactant cetyltrimethylammonium bromide (CTAC), and the structure of the hollow mesoporous microspheres can be controlled, and the functionalized microspheres can be modified, the -OH contained on the surface of the microspheres is oxidized to-COOH under the action of concentrated sulfuric acid and ammonium persulfate, then reacts with methoxypolyethylene glycol amine to make-COOH graft PEG-NH2 functional group, effectively improve the hydrophilicity of the material, enhance the drug loading performance of sample to doxorubicin (DOX), by changing the volume ratio of water and ethanol in solvent, obtain 3 groups of polymer microspheres with different particle sizes, the results show that, solvent has significant influence on microsphere particle size in the reaction process, the volume ratio of ethanol and water is from 4:19, 8:19 to 16:19, the particle size of microsphere is continuously increased, and the drug loading is also increased.

The application provides a use of Di'ao Xin-xue-kang in preparation of a medicine for preventing doxorubicin-induced cardiac endothelial injury toxicity, and belongs to the field of medicines. The application uses Di'ao Xin-xue-kang for preventive administration, protects early cardiac endothelial injury induced by doxorubicin, and further can rescue or avoid occurrence of subsequent irreversible cardiotoxicity, especially uses Di'ao Xin-xue-kang for prevention or / and intervention of asymptomatic cardiac dysfunction related to cancer treatment, and opens a new use and administration method for clinical use of Di'ao Xin-xue-kang.

The present application belongs to the field of biological medicine, and relates to a traditional Chinese medicine composition for treating chronic heart failure. The traditional Chinese medicine composition comprises the following traditional Chinese medicinal materials or is prepared based on raw medicinal materials comprising the following traditional Chinese medicines: Astragalus membranaceus (Fisch.) Bunge, Acanthopanax senticosus, black ginseng, Leonurus japonicus Houtt., Ophiopogon japonicus (Thunb.) Ker-Gawl., Eutrema latifolium, Schisandra chinensis (Turcz.) Baill., Cinnamomum cassia Presl and Polygonatum sibiricum. Clinical test results show that the traditional Chinese medicine composition significantly increases the systolic pressure and diastolic pressure of heart failure patients when treating chronic heart failure patients, not only has a significant effect, but also has a rapid effect. In addition, the traditional Chinese medicine composition significantly reduces the degree of cardiac inflammation and significantly improves the cardiac function in an experimental autoimmune myocarditis mouse model. In an adriamycin-induced heart failure model SD rat, the traditional Chinese medicine composition also significantly improves the cardiac function, showing good treatment potential.

The application relates to application of glycolipid compound PF60 in preparation of a tumor drug resistance reversing agent or a tumor drug sensitizer, and belongs to the technical field of biochemical application. The structure of the glycolipid compound PF60 is shown in the following formula: the drug or the tumor drug is adriamycin. Research shows that the glycolipid compound PF60 has the activity of reversing MCF-7 / ADR when being combined with adriamycin at concentrations of 5, 10 and 20 mu g / mL respectively.

The invention provides a chemotherapy combined medicine and application thereof. The chemotherapy combined medicine comprises a first medicine and a second medicine, the first drug is a platinum chemotherapeutic drug or adriamycin, and the second drug is a zinc nitroprusside nano-drug; the zinc nitroprusside nano-drug is formed by coordination self-assembly of sodium nitroprusside and a zinc ion source compound. The zinc nitroprusside nano-drug has glutathione responsiveness and can release nitric oxide and zinc ions. In the platinum chemotherapy combined medicine, the cis-platinum and the ZnNO play a synergistic interaction role.

The invention discloses application of NINJ1 in treatment of adriamycin-induced myocardial injury, and relates to the field of biological medicine. The NINJ1 is applied to preparation of a medicine for preventing and / or treating adriamycin-induced myocardial injury, and the application comprises the step of achieving the purpose of preventing and / or treating adriamycin-induced myocardial cell injury, cardiac insufficiency, myocardial fibrosis or heart failure by inhibiting expression or activity of NINJ1. Wherein the mode of inhibiting the NINJ1 comprises the use of an NINJ1 inhibitor, the knockout of an NINJ1 gene or the silencing of the NINJ1 gene. The key effect of the NINJ1 in doxorubicin cardiotoxicity is disclosed for the first time, the NINJ1 is determined as a new therapeutic target, a new direction and theoretical basis are provided for development of drugs for preventing and treating doxorubicin cardiotoxicity, and the NINJ1 has important clinical value.

The application relates to application of glycolipid compound PF35 in preparation of a tumor drug resistance reversing agent or a tumor drug sensitizer, and belongs to the technical field of biochemical application. The structure of the glycolipid compound PF35 is shown in the following formula: the drug or the tumor drug is adriamycin. Research shows that the glycolipid compound PF35 has the activity of reversing MCF-7 / ADR when being combined with adriamycin at concentrations of 5, 10 and 20 mu g / mL respectively.

The invention belongs to the technical field of tumor drugs, and particularly relates to an intelligent nano bionic drug delivery system based on ZIF-8, a preparation method and application, adriamycin, DNAzyme and an aptamer are loaded on ZIF-8, and the preparation method comprises the steps that after adriamycin is loaded to a ZIF-8 nano carrier, DNAzyme is further adsorbed by means of electrostatic interaction, and the ZIF-8 nano carrier is loaded with the DNAzyme; the intelligent nano bionic drug delivery system based on ZIF-8 is characterized in that a DOX / Dz-coated ZIF-8-RM / Apt nano drug delivery system is prepared by using a DOX / Dz-coated ZIF-8-RM / Apt nano drug delivery system, then using an erythrocyte membrane to perform surface modification, and finally inserting an aptamer drug into the surface of the cytomembrane through a lipid insertion method, and the intelligent nano bionic drug delivery system based on ZIF-8 is used for relieving chemotherapy drug resistance and improving the anti-tumor immunity efficiency; and the effect of the medicine in the tumor is improved to the greatest extent.